Drug Master Files (DMF) MCQs With Answer

Introduction

Drug Master Files (DMFs) are a cornerstone of regulatory submissions, allowing confidential chemistry, manufacturing, and controls (CMC) information to be reviewed by agencies without disclosing trade secrets to applicants. This quiz is designed for M. Pharm students studying Regulatory Affairs (MPH 104T) to sharpen understanding of DMF scope, types, structure, eCTD requirements, Letters of Authorization (LoA), updates, and compliance nuances under FDA and related global frameworks. You will encounter practical scenarios on Type II API DMFs, GDUFA implications, deficiency handling, change control, and how DMFs interface with ANDA/NDA reviews. Each question emphasizes regulatory logic and good dossier practice so you can confidently navigate real-world submissions and interactions with regulators.

Q1. What is the primary purpose of a Drug Master File (DMF)?

• To secure patent protection for a new molecule
• To permit confidential submission of detailed CMC information to FDA for reference by multiple applications without disclosure to applicants
• To replace the need for an NDA/ANDA
• To publish manufacturing processes in the public domain

Correct Answer: To permit confidential submission of detailed CMC information to FDA for reference by multiple applications without disclosure to applicants

Q2. Which DMF types are currently accepted by US FDA (CDER) for new submissions?

• Type II, Type III, Type IV, and Type V
• Type I through Type V
• Type I only
• Type VI only

Correct Answer: Type II, Type III, Type IV, and Type V

Q3. A Type II DMF typically covers which of the following?

• Drug substance, drug substance intermediates, and materials used in their manufacture
• Container-closure systems and packaging components
• Excipients, colorants, flavors, and essences
• Clinical study reports

Correct Answer: Drug substance, drug substance intermediates, and materials used in their manufacture

Q4. Under GDUFA, which DMF type triggers a one-time user fee when first referenced by an ANDA?

• Type II API DMF
• Type III Packaging DMF
• Type IV Excipient DMF
• Type V DMF

Correct Answer: Type II API DMF

Q5. What is the correct handling of a Letter of Authorization (LoA) for a DMF?

• Submit only to the applicant; FDA does not require a copy
• Submit only to FDA; the applicant should not receive a copy
• Submitted to FDA (citing the DMF number) with a copy provided to the authorized party/applicant
• Submitted to the EMA and WHO simultaneously

Correct Answer: Submitted to FDA (citing the DMF number) with a copy provided to the authorized party/applicant

Q6. For CDER, how must new DMFs be submitted as of the 2018 mandate?

• In paper CTD format with two copies
• In electronically signed PDFs by email
• In eCTD format via the Electronic Submissions Gateway
• As printed binders provided during inspections

Correct Answer: In eCTD format via the Electronic Submissions Gateway

Q7. In the CTD structure for a DMF, which module predominantly contains quality/CMC details?

• Module 1
• Module 2
• Module 3
• Module 5

Correct Answer: Module 3

Q8. What should a DMF annual update typically include?

• Marketing forecasts and pricing
• A list of authorized parties and a summary of changes (or a statement of no changes) since the last update
• Complete revalidation of all methods annually
• Environmental assessment for the manufacturing site

Correct Answer: A list of authorized parties and a summary of changes (or a statement of no changes) since the last update

Q9. How does FDA communicate DMF deficiencies identified during review?

• Directly to the DMF holder; the referencing applicant is notified that deficiencies exist but not given proprietary details
• Only to the referencing applicant with full proprietary details
• By publishing on FDA’s website
• Through the local health authority only

Correct Answer: Directly to the DMF holder; the referencing applicant is notified that deficiencies exist but not given proprietary details

Q10. Under what condition may FDA inactivate a DMF?

• After one month without an LoA
• If it has not been referenced in a submission for two years and lacks required updates
• Whenever multiple applicants reference it
• If the holder changes its company logo

Correct Answer: If it has not been referenced in a submission for two years and lacks required updates

Q11. Which statement about Type V DMFs is correct?

• They are intended for clinical protocols
• They are accepted without conditions for any content
• Their use generally requires prior agreement with FDA regarding the appropriateness of the content
• They are reserved exclusively for packaging components

Correct Answer: Their use generally requires prior agreement with FDA regarding the appropriateness of the content

Q12. Which of the following is NOT typically appropriate content for a DMF?

• Detailed manufacturing process description
• Specifications and analytical methods
• Stability data supporting retest period/shelf-life
• Commercial pricing agreements with applicants

Correct Answer: Commercial pricing agreements with applicants

Q13. What is the European mechanism most analogous to the US DMF for APIs?

• ASMF (Active Substance Master File)
• 510(k)
• IDE
• USP General Chapter

Correct Answer: ASMF (Active Substance Master File)

Q14. In Europe, which document can obviate the need for an ASMF by demonstrating API suitability to the Ph. Eur. monograph?

• Certificate of Pharmaceutical Product (CoPP)
• Certificate of Suitability (CEP) from EDQM
• Certificate of Analysis (CoA)
• WHO Prequalification certificate

Correct Answer: Certificate of Suitability (CEP) from EDQM

Q15. Which confidentiality statement regarding DMFs is true?

• FDA will not disclose DMF contents to the applicant without the holder’s permission
• Applicants can obtain full copies of DMFs through FOIA
• DMFs become public documents upon the first reference
• DMFs must be shared with all referencing applicants in full

Correct Answer: FDA will not disclose DMF contents to the applicant without the holder’s permission

Q16. Which change would generally be considered major and warrant prompt DMF amendment and notification to authorized parties?

• Correction of a typographical error in a non-critical section
• Administrative change in a contact person’s phone number
• Change in the synthetic route or critical process parameters that may impact quality
• Update to the list of distributors

Correct Answer: Change in the synthetic route or critical process parameters that may impact quality

Q17. For a Type III Packaging DMF, which data set is most relevant?

• Clinical efficacy endpoints
• Bioequivalence study reports
• Container-closure system description, composition, specifications, and extractables/leachables risk assessment/data
• Labeling promotional claims

Correct Answer: Container-closure system description, composition, specifications, and extractables/leachables risk assessment/data

Q18. Who can be a DMF holder?

• The manufacturer of an API, excipient, or packaging component
• FDA review chemist
• A retail pharmacy
• A patient advocacy group

Correct Answer: The manufacturer of an API, excipient, or packaging component

Q19. What is the correct regulatory action when a DMF holder wishes to withdraw a Letter of Authorization for a specific applicant?

• FDA automatically inactivates the entire DMF
• The holder sends a withdrawal notice to FDA and notifies the affected applicant(s)
• The applicant must destroy all records and no notification is needed
• No action is possible once an LoA is issued

Correct Answer: The holder sends a withdrawal notice to FDA and notifies the affected applicant(s)

Q20. Which statement best describes FDA’s treatment of DMFs during review?

• DMFs are not approved or rejected independently; they are reviewed when referenced by an application
• DMFs are approved documents similar to NDAs
• DMFs must include clinical data for acceptance
• DMFs eliminate the need for CMC review in the application

Correct Answer: DMFs are not approved or rejected independently; they are reviewed when referenced by an application

Download